Clovis Oncology (NASDAQ:CLVS) shares are surging in today’s pre-market trade after its Rubraca demonstrated progression-free survival versus placebo for ovarian cancer.
Don't Miss Our Christmas Offers:
- Discover the latest stocks recommended by top Wall Street analysts, all in one place with Analyst Top Stocks
- Make smarter investments with weekly expert stock picks from the Smart Investor Newsletter
The company presented the data from the supporting ATHENA trial at the European Society of Medical Oncology (ESMO) Congress in Paris.
More details to follow…
Read full Disclosure
